CENTURY II

Overview

Comparable clinical outcomes of Ultimaster™ stent with bioresorable polymer coating versus Xience stent with durable polymer coating are maintained up to five years.
Particularly remarkable was the low rate of very late stent thrombosis (0.2%) in both arms.
These data supports the long term safe use and good performance of the Ultimaster™ DES.

	Ultimaster N=551 pts	Xience N=550 pts	P
Age, years (mean ±SD)	65.2+10.5	65.5+10.6	0.61
Gender - male, %	78.6	82.4	0.11
DM, %	31.9	30.9	0.71
IDDM, %	16.5	14.7	0.65
Hypertension, %	73.3	67.8	0.05
Current Smoker, %	22.2	23.9	0.50
Previous smaker, %	46.7	42.0	0.12
Previous MI, %	28.3	27.6	0.80
Previous PCI, %	37.2	35.0	0.45
Previous CABG, %	4.5	3.7	0.46
Peripheral vascular discase, %	9.6	6.6	0.06
High risk ACS, %	22.5	24.7	0.39

	Ultimaster N=551 pts Nlesions=711	Xience N-550 pts Nlesions=716	P
Multi-vessel disease, %	39.6	41.3	0.56
Lesions detected ,n	2.0±1.3	2.0±1.3	0.67
Lesions treated,n	1.3±0.6	1.3±0.6	0.62
Bifurcation/lesion, %	13.8	14.4	0.74
Ostial/lesion, %	6.0	8.4	0.08
Moderate/severe calcification, %	21.5	17.7	0.70
Access site, % 　Radial 　Femoral	71.7 26.7	73.1 25.6	0.55
N° of stents implanted/pt	1.5±0.8	1.6±0.9	0.94
Total implanted stent length/pt	29.5±17.0	29.6±18.1	0.66
Delivery success, %	99.1	99.5	0.23
Procedure success/pt, %	98.0	98.2	0.83